Enfortumab Vedotin After Pd-1 Or Pd-L1 Inhibitors In Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma (Ev-201): A Multicentre, Single-Arm, Phase 2 Trial (Vol 22, Pg 872, 2021)
LANCET ONCOLOGY（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要